Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study

被引：0
|
作者：
Sakae Tanaka
Hideki Mizutani
Eri Tsuruya
Ryoko Fukuda
Kiyoka Kuge
Naoki Okubo
机构：
[1] The University of Tokyo,Department of Orthopaedic Surgery, Graduate School of Medicine
[2] Daiichi Sankyo Co.,Post Marketing Study Department
[3] Ltd.,Biostatistics and Data Management Department
[4] Daiichi Sankyo Co.,undefined
[5] Ltd.,undefined
来源：
Journal of Bone and Mineral Metabolism | 2021年 / 39卷
关键词：
Denosumab; Hypocalcaemia; Japanese; Osteoporosis; Real-world survey;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：463 / 473
页数：10
相关论文
共 50 条
  • [1] Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study
    Tanaka, Sakae
    Mizutani, Hideki
    Tsuruya, Eri
    Fukuda, Ryoko
    Kuge, Kiyoka
    Okubo, Naoki
    JOURNAL OF BONE AND MINERAL METABOLISM, 2021, 39 (03) : 463 - 473
  • [2] Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study
    Yamamoto, Fumiko
    Unno, Yuriko
    Okamura, Tomoo
    Ikeda, Rie
    Ochiai, Kaori
    Hayashi, Naoyuki
    DIABETES THERAPY, 2020, 11 (01) : 107 - 117
  • [3] Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study
    Fumiko Yamamoto
    Yuriko Unno
    Tomoo Okamura
    Rie Ikeda
    Kaori Ochiai
    Naoyuki Hayashi
    Diabetes Therapy, 2020, 11 : 107 - 117
  • [4] Long-Term Safety and Effectiveness of Thyrotropin Alfa in Japanese Patients: A Post-Marketing Surveillance Study
    Rie Kanamori
    Shiho Yamane
    Takeshi Seto
    Advances in Therapy, 2021, 38 : 4949 - 4960
  • [5] Long-Term Safety and Effectiveness of Thyrotropin Alfa in Japanese Patients: A Post-Marketing Surveillance Study
    Kanamori, Rie
    Yamane, Shiho
    Seto, Takeshi
    ADVANCES IN THERAPY, 2021, 38 (09) : 4949 - 4960
  • [6] Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study
    Yabe, Daisuke
    Yamamoto, Fumiko
    Lund, Soren S.
    Okamura, Tomoo
    Kadowaki, Takashi
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (10) : 1303 - 1313
  • [7] Safety and effectiveness of denosumab in Japanese patients with rheumatoid arthritis: A 2-year post-marketing surveillance study
    Tanaka, Yoshiya
    Mizutani, Hideki
    Fujii, Kunimitsu
    Okubo, Naoki
    MODERN RHEUMATOLOGY, 2023, 34 (05) : 927 - 935
  • [8] Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance
    Ito, Tomohiro
    Naito, Yusuke
    Shimmoto, Naoki
    Ochiai, Kaori
    Hayashi, Naoyuki
    Okamura, Tomoo
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (03) : 363 - 371
  • [9] Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
    Kaku, Kohei
    Yamamoto, Kazuhiro
    Fukushima, Yumiko
    Lliev, Hristo
    Yasui, Atsutaka
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (10) : 1315 - 1328
  • [10] Long-term safety and effectiveness of omalizumab in Japanese paediatric patients with severe allergic asthma: A post-marketing surveillance
    Nakamura, N.
    Kashitani, Y.
    Yoshisue, H.
    Nagasaki, M.
    Sasajima, T.
    ALLERGY, 2020, 75 : 364 - 365
12345